Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Timothy S. Dutill
Advertisement
Timothy S. Dutill is the process development specialist II at the Infections Disease Research Institute
Articles by Timothy S. Dutill
Advertisement
Latest Updated Articles
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNsPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
2
AstraZeneca Lupus Treatment Support in EU Opens Door for Self-Administration Options
3
Biopharma’s Digital Hopes Versus Actual Implementation
4
Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions
5
